Otros idiomas I-Mab BOERSE MUENCHEN

Acciones

0VY

US44975P1030

En tiempo real BOERSE MUENCHEN Otros sitios de cotización 21:44:03 27/06/2024			Varia. Cinco días.	Varia. 1 de enero.
1,58 ^EUR	-2,47 %		-2,41 %	-2,99 %

06/06	I-Mab nombra a Phillip Dennis director médico	CI
05/06	I-Mab colabora con Bristol-Myers para evaluar Givastomig en un estudio combinado para cánceres gástricos y esofágicos	MT

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	07/06
I-Mab Appoints Phillip Dennis as Chief Medical Officer	06/06
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024	23/05
I-Mab to Participate at the Jefferies Global Healthcare Conference	22/05
I-MAB Filed 2023 Annual Report on Form 20-F	30/04
Verastem Names John Hayslip as Chief Medical Officer	18/04
I-Mab Announces Chief Medical Officer Changes	15/04
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	08/04
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	05/04
I-Mab Completes Business Divestiture in China	02/04
I-Mab Announces Closing of the Divestiture of Business Operations in China	02/04
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	02/04
I Mab : Resignations of Director and Senior Management - Form 6-K	01/04
I-Mab Announces Executive Resignation	01/04
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02
I-Mab Divests China Operations, Shifts Focus to US Market	09/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas I-Mab BOERSE MUENCHEN

Acciones

0VY

US44975P1030

Otros idiomas

Filtros